Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jan
21
Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
Jan
19
UCB to acquire Zogenix
Jan
18
Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
Dec
16
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial
Dec
10
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
Nov
19
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms
Nov
05
UCB Showcases Key Rheumatology Data at ACR Convergence 2021
Oct
16
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Sep
29
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress